Angiogenesis and tumour progression: Migration-stimulating factor as a novel target for clinical intervention

Eye

Volumn 24, Issue 3, 2010, Pages 450-458

  Schor, A M ^a   Schor, S L ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

5 azacytidine; Angiogenesis; Cancer; Epigenetics; Metastasis; MSF

Indexed keywords

FIBRONECTIN; MIGRATION STIMULATING FACTOR;

ANGIOGENESIS; CONFERENCE PAPER; DOWN REGULATION; DRUG ACTIVITY; GENE EXPRESSION; HUMAN; MOLECULAR CLONING; MOLECULAR MECHANICS; NONHUMAN; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; THERAPY EFFECT; TREATMENT OUTCOME; TUMOR GROWTH;

EID: 77949477173     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/eye.2009.314     Document Type: Conference Paper

References (44)

1. Folkman J, Hanahan D. Switch to the angiogenic phenotype during tumorigenesis. Princess Takamatsu Symp 1991; 22: 339-347.
2. Folkman J. The role of angiogenesis in tumor growth. Semin Cancer Biol 1992; 3: 65-71.
3. Naumov GN, Folkman J, Straume O, Akslen LA. Tumorvascular interactions and tumor dormancy. APMIS 2008; 116: 569-585.
4. Simó R, Carrasco E, García-Ramírez M, Hernández C. Angiogenic and antiangiogenic factors in proliferative diabetic retinopathy. Curr Diabetes Rev 2006; 2: 71-98.
5. Szekanecz Z, Koch AE. Mechanisms of disease: angiogenesis in inflammatory diseases. Nat Clin Pract Rheumatol 2007; 3: 635-643.
6. Friedlander M. Fibrosis and diseases of the eye. J Clin Invest 2007; 117: 576-586.
7. Ciulla TA, Rosenfeld PJ. Antivascular endothelial growth factor therapy for neovascular age-related macular degeneration. Curr Opin Ophthalmol 2009; 20: 158-165.
8. Ziemssen F, Grisanti S, Bartz-Schmidt KU, Spitzer MS. Offlabel use of bevacizumab for the treatment of age-related macular degeneration: what is the evidence? Drugs Aging 2009; 26: 295-320.
9. Carmeliet P, De Smet F, Loges S, Mazzone M. Branching morphogenesis and antiangiogenesis candidates: tip cells lead the way. Nat Rev Clin Oncol 2009; 6: 315-326.
10. Chi AS, Sorensen AG, Jain RK, Batchelor TT. Angiogenesis as a therapeutic target in malignant gliomas. Oncologist 2009; 14: 621-636.
11. Furuya M, Yonemitsu Y, Aoki III I. Angiogenesis: complexity of tumor vasculature and microenvironment. Curr Pharm Des 2009; 15: 1854-1867.
12. Economou MA. Uveal melanoma and macular degeneration: molecular biology and potential therapeutic applications. Acta Ophthalmol 2008; 86: 930-931.
13. Frank RN. Treating diabetic retinopathy by inhibiting growth factor pathways. Curr Opin Investig Drugs 2009; 10: 327-335.
14. Folkman J, Shing Y. Angiogenesis. J Biol Chem 1992; 267: 10931-10934.
15. Schor AM, Schor SL. Tumour angiogenesis: a review. J Pathol 1983; 141: 385-413.
16. Schor SL, Schor AM, Grey AM, Rushton G. Fetal and cancer patient fibroblasts produce an autocrine migrationstimulating factor not made by normal adult cells. J Cell Sci 1988; 90: 391-399.
17. Schor SL, Schor AM, Rushton G. Fibroblasts from cancer patients display a mixture of both fetal and adult-like phenotypic characteristics. J Cell Sci 1988; 90: 401-407.
18. Schor AM, Rushton G, Ferguson JE, Howell A, Redford J, Schor SL. Phenotypic heterogeneity in breast fibroblastsFfunctional anomaly in fibroblasts from histologically normal tissue adjacent to carcinoma. Int J Cancer 1994; 59: 25-32.
19. Schor SL, Schor AM. Stromal acceleration of tumour progression: role of fetal-like fibroblast subpopulations. Pathol Update 1997; 4: 75-95.
20. Schor SL, Ellis IR, Jones SJ, Baillie R, Seneviratne K, Clausen J et al. Migration-stimulating factor: a genetically truncated onco-fetal fibronectin isoform expressed by carcinoma and tumor-associated stromal cells. Cancer Res 2003; 63: 8827-8836.
21. Hu H, Ran Y, Zhang Y, Zhou Z, Harris SJ, Yu L et al. Antibody library-based tumor endothelial cells surface proteomic functional screen reveals migration-stimulating factor as an anti-angiogenic target. Mol Cell Proteomics 2009; 8: 816-826.
22. Hynes R. Fibronectins. Springer-Verlag: New York, 1990.
23. Kay RA, Ellis IR, Jones SJ, Perrier S, Florence MM, Schor AM et al. The expression of MSF, a potent oncofetal cytokine, is uniquely controlled by 30-untranslated region dependent nuclear sequestration of its precursor messenger RNA. Cancer Res 2005; 65: 10742-10749.
24. Bakheet T, Frevel M, Williams BRG, Greer W, Khabar KSA. ARED: human AU-rich element-containing mRNA database reveals an unexpectedly diverse functional repertoire of encoded proteins. Nucleic Acids Res 2001; 29: 246-254.
25. Zhao Q, Liu X, Collodi P. Identification and characterization of a novel fibronectin in Zebrafish. Exp Cell Res 2001; 268: 211-221.
26. Liu X, Zhao Q, Collodi P. A truncated form of fibronectin is expressed in fish and mammals. Matrix Biol 2003; 22: 393-396.
27. Schor SL, Schor AM. Tumour-stroma interactionsFphenotypic and genetic alterations in mammary stroma: implications for tumour progression. Breast Cancer Res 2001; 3: 373-379.
28. Schor SL, Schor AM, Grey AM, Chen J, Rushton G, Grant ME et al. Mechanism of action of the migration stimulating factor produced by fetal and cancer-patient fibroblasts: effect on hyaluronic acid synthesis. In Vitro Cell Dev Biol 1989; 25: 737-746.
29. Houard X, Germain S, Gervais M, Michaud A, van den Brule F, Foidart J-M et al. Migration-stimulating factor displays HEXXH-dependent catalytic activity important for promoting tumor cell migration. Int J Cancer 2005; 116: 378-384.
30. Schor SL, Ellis I, Banyard J, Schor AM. Motogenic activity of the IGD amino acid motif. J Cell Sci 1999; 112: 3879-3888.
31. Millard CJ, Ellis IR, Pickford AR, Schor AM, Schor SL, Campbell ID. The role of fibronectin IGD motif in stimulating fibroblast migration. J Biol Chem 2007; 282: 35530-35535.
32. Vakonakis I, Staunton D, Ellis IR, Starkies P, Flanagan A, Schor AM et al. Motogenic sites in human fibronectin are masked by long range interactions. J Biol Chem 2009; 284: 15668-15675.
33. Nathan C, Sporn M. Cytokines in context. J Cell Biol 1991; 113: 981-986.
34. Schor SL. Cytokine control of cell motility: modulation and mediation by the extracellular matrix. Prog Growth Factor Res 1994; 5: 223-248.
35. Pardali E, ten Dijke P. Transforming growth factor-beta signaling and tumor angiogenesis. Front Biosci 2009; 14: 4848-4861.
36. Padua D, Massague J. Role of TGF-b in metastasis. Cell Res 2009; 19: 89-102.
37. Ellis I, Grey AM, Schor AM, Schor SL. Antagonistic effects of TGF-b1 and MSF on fibroblast migration and hyaluronic acid synthesisFpossible implications for dermal wound healing. J Cell Sci 1992; 102: 447-456.
38. Jones SJ, Florence MM, Ellis IR, Kankova K, Schor SL, Schor AM. Co-expression by keratinocytes of migration stimulating factor (MSF) and functional inhibitor of its bioactivity (MSFI). Exp Cell Res 2007; 313: 4145-4157.
39. Schor AM, Schor SL, Allen TD. The effects of culture conditions on the proliferation and morphology of bovine aortic endothelial cells in vitro: reversible expression of the sprouting cell phenotype. J Cell Sci 1983; 62: 267-285.
40. Schor AM, Ellis I, Schor SL. Collagen gel assay for angiogenesis. Induction of endothelial cell sprouting. In: Murray JC (ed). Methods in Molecular Medicine, Vol 46: Angiogenesis Protocols. Humana Press Inc: Totowa, NJ, 2001, pp 145-162.
41. Bissell MJ, Barcellos-Hoff MH. The influence of extracellular matrix on gene expression: is structure the message? J Cell Sci 1987; 8(Suppl 10): 327-343.
42. Xu R, Boudreau A, Bissell MJ. Tissue architecture and function: dynamic reciprocity via extra-and intra-cellular matrices. Cancer Metastasis Rev 2009; 28: 167-176.
43. Yoshino I, Kometani T, Shoji F, Osoegawa A, Ohba T, Kouso H et al. Induction of epithelial-mesenchymal transitionrelated genes by benzo[a]pyrene in lung cancer cells. Cancer 2007; 110: 369-374.
44. Schor SL, Schor AM, Keatch RP, Belch JFF. Role of matrix macromolecules in the aetiology and treatment of chronic ulcers. In: Lee BY (ed). The Wound Management Manual. McGraw Hill: New York, Chapter 10 2005, pp 109-121.